Yubing WANG

Dr. Yubing WANG

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Cancer Letters
Verified
Journal Article
Closed access
XLXiaocheng Li
Xiaocheng Li
WDWenbin Diao
Wenbin Diao
HXHantao Xue
Hantao Xue
FWFei Wu
Fei Wu
WWWeiyu Wang
Weiyu Wang
ZGZhiqin Gao
Zhiqin Gao

26 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
TLTian Liu
Tian Liu
YWYiwei Wang
Yiwei Wang
YWYubing WANG
Yubing WANG
ACAndrew Chan
Andrew Chan
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor gene frequently found to be inactivated in over 30% of human cancers. PTEN encodes a 54-kDa lipid phosphatase that serves as a gatekeeper of the phosphoinositide 3-kinase pathway involved in the promotion of multiple pro-tumorigenic phenotypes. Although the PTEN protein plays a pivotal role in carcinogenesis, cumulative evidence has implicated it as a key signaling molecule in several other diseases as well, such as diabetes, Alzheimer’s disease, and autism spectrum disorders. This finding suggests that diverse cell types, especially differentiated cells, express PTEN. At the cellular level, PTEN is widely distributed in all subcellular compartments and organelles. Surprisingly, the cytoplasmic compartment, not the plasma membrane, is the predominant subcellular location of PTEN. More recently, the finding of a secreted ‘long’ isoform of PTEN and the presence of PTEN in the cell nucleus further revealed unexpected biological functions of this multifaceted molecule. At the regulatory level, PTEN activity, stability, and subcellular distribution are modulated by a fascinating array of post-translational modification events, including phosphorylation, ubiquitination, and sumoylation. Dysregulation of these regulatory mechanisms has been observed in various human diseases. In this review, we provide an up-to-date overview of the knowledge gained in the last decade on how different functional domains of PTEN regulate its biological functions, with special emphasis on its subcellular distribution. This review also highlights the findings of published studies that have reported how mutational alterations in specific PTEN domains can lead to pathogenesis in humans.

1 November 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
FWFei Wu
Fei Wu
HXHantao Xue
Hantao Xue
XLXiaocheng Li
Xiaocheng Li
WDWenbin Diao
Wenbin Diao
BJBin Jiang
Bin Jiang
GZGao Zhi-Qin
Gao Zhi-Qin
Hepatocellular carcinoma (HCC), a common malignancy in China and globally, is primarily treated through surgical resection and liver transplantation, with chemotherapy as a significant synergistic option. Adenine (Ade), a nucleobase, exhibits antitumor effects by blocking human hepatic carcinoma cells in S phase and inhibiting tumor cell proliferation. However, its use is limited owing to its low solubility, poor targeting ability, and nephrotoxicity. Therefore, liver-targeting drug delivery systems have attracted considerable attention for the treatment of HCC. In this study, we explored the liver-targeting efficacy and antitumor effect of adenine-loaded glycyrrhetinic acid-modified hyaluronic acid (Ade/GA-HA) nanoparticles in vitro and in vivo. The GA-HA nanoparticles possessed obvious targeting specificity toward liver cancer cells, which was mainly achieved by the specific binding of the GA ligand to the GA receptor that was highly expressed on the liver cell membrane. In vitro and in vivo results showed that Ade/GA-HA nanoparticles could inhibit liver cancer cell proliferation and migration, promote apoptosis, and significantly inhibit the growth of tumor tissues. Altogether, this study is the first to successfully demonstrate that the targeting activity and antitumor effect of Ade against HCC are enhanced by using GA-HA nanoparticles in vitro and in vivo.

2 December 2023 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
XZXiaoyan Zeng
Xiaoyan Zeng
SCStanley K. K. Cheung
Stanley K. K. Cheung
MSMengqi Shi
Mengqi Shi
POPenelope M. Y. Or
Penelope M. Y. Or
ZLZhining Li
Zhining Li
ACAndrew Chan
Andrew Chan
Glial cell-mediated neuroinflammation and neuronal attrition are highly correlated with cognitive impairment in Alzheimer’s disease. YKL-40 is a secreted astrocytic glycoprotein that serves as a diagnostic biomarker of Alzheimer’s disease. High levels of YKL-40 are associated with either advanced Alzheimer’s disease or the normal aging process. However, the functional role of YKL-40 in Alzheimer’s disease development has not been firmly established. In a 5xFAD mouse model of Alzheimer’s disease, we observed increased YKL-40 expression in the cerebrospinal fluid of 7-month-old mice and was correlated with activated astrocytes. In primary astrocytes, Aβ1-42 upregulated YKL-40 in a dose-dependent manner and was correlated with PI3-K signaling pathway activation. Furthermore, primary neurons treated with YKL-40 and/or Aβ1-42 resulted in significant synaptic degeneration, reduced dendritic complexity, and impaired electrical parameters. More importantly, astrocyte-specific knockout of YKL-40 over a period of 7 days in symptomatic 5xFAD mice could effectively reduce amyloid plaque deposition in multiple brain regions. This was also associated with attenuated glial activation, reduced neuronal attrition, and restored memory function. These biological phenotypes could be explained by enhanced uptake of Aβ1-42 peptides, increased rate of Aβ1-42 degradation and acidification of lysosomal compartment in YKL-40 knockout astrocytes. Our results provide new insights into the role of YKL-40 in Alzheimer’s disease pathogenesis and demonstrate the potential of targeting this soluble biomarker to alleviate cognitive defects in symptomatic Alzheimer’s disease patients.

1 August 2018 in Cancer Letters
Verified
Journal Article
Closed access
YWYubing WANG
Yubing WANG
CWChi Wai Wong
Chi Wai Wong
MYMingfei Yan
Mingfei Yan
LLLisha Li
Lisha Li
TLTian Liu
Tian Liu
ACAndrew Chan
Andrew Chan

9 August 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
HXHantao Xue
Hantao Xue
LQLiya Qin
Liya Qin
LZLongxiang Zhang
Longxiang Zhang
XLXiaocheng Li
Xiaocheng Li
FWFei Wu
Fei Wu
GZGao Zhi-Qin
Gao Zhi-Qin
Liver cancer is one of the most common malignancies worldwide and poses a serious threat to human health. The most important treatment method, liver cancer chemotherapy, is limited due to its high toxicity and poor specificity. Targeted drug delivery systems have emerged as novel therapeutic strategies that deliver precise, substantial drug doses to target sites via targeting vectors and enhance the therapeutic efficacy. In the present study, glycyrrhetinic acid‑modified hyaluronic acid (GA‑HA) was used as a carrier for the model drug docetaxel (DTX) to prepare DTX‑loaded GA‑HA nanoparticles (DTX/GA‑HA‑NPs). The results indicated that the DTX/GA‑HA‑NPs exhibited high monodispersity (particle dispersity index, 0.209±0.116) and desirable particle size (208.73±5.0 nm) and zeta potential (‑27.83±3.14 mV). The drug loading capacity and encapsulation efficiency of the NPs were 12.59±0.68 and 85.38±4.62%, respectively. Furthermore, it was determined that FITC‑GA‑HA was taken up by cells and distributed in the cytoplasm. DTX and DTX/GA‑HA (just the DTX delivered by the nanoparticle) aggregated and altered the structure of cellular microtubules. Compared with DTX alone, DTX/GA‑HA‑NPs had a stronger inhibitory effect on HepG2 cell proliferation and promoted apoptosis of HepG2 cells. All experimental results indicated that DTX/GA‑HA‑NPs were successfully prepared and had liver‑targeting and antitumor activities in vitro, which provided a foundation for future in vivo studies of the antitumor effects of DTX/GA‑HA‑NPs.